Flexion Therapeutics Company Profile (NASDAQ:FLXN)

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $931.2 million
  • Outstanding Shares: 31,905,000
Average Prices:
  • 50 Day Moving Avg: $25.18
  • 200 Day Moving Avg: $22.57
  • 52 Week Range: $15.93 - $32.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.31
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.38 per share
  • Price / Book: 3.81
Profitability:
  • EBITDA: ($87,640,000.00)
  • Return on Equity: -53.94%
  • Return on Assets: -38.24%
Debt:
  • Debt-to-Equity Ratio: 0.74%
  • Current Ratio: 18.29%
  • Quick Ratio: 18.29%
Misc:
  • Average Volume: 1.01 million shs.
  • Beta: 1.12
  • Short Ratio: 11.24
 

Frequently Asked Questions for Flexion Therapeutics (NASDAQ:FLXN)

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.11. View Flexion Therapeutics' Earnings History.

Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?

9 brokerages have issued 12-month price targets for Flexion Therapeutics' stock. Their predictions range from $0.02 to $570.00. On average, they expect Flexion Therapeutics' share price to reach $88.50 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.

What are analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (10/17/2017)
  • 2. Cantor Fitzgerald analysts commented, "OpEx Increases in 2017: FLXN reported 4Q16 and YE results of ($0.79) and ($2.84), below our estimates due to higher R&D and SG&A expense. Management noted on the call that R&D expense should increase given the on going repeat-dose study and manufacturing ramp with SG&A ramping through the 2H17 as launch preparation get fully underway. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. We have adjusted our estimates to reflect quarter results. PDUFA and Beyond: We view the acceptance of the NDA without the need to provide additional data as an incremental positive, removing an overhang in the minds of some investors. We see investors now turning to the prospective label with the potential for differentiation in the diabetic sub-population and a repeat- dose sNDA filing which could be on label by 2019. Additional label expansion into other joints including shoulder and hip are also possibilities though not near term." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Chairman of the Board
  • Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director
  • Neil Bodick M.D., Ph.D., Chief Scientific Officer
  • Mark Levine, Vice President, General Counsel
  • John Magee, Vice President - Sales
  • Mark Fraga, Vice President - Marketing
  • Scott Kelley M.D., Vice President - Medical Affairs
  • Dan Thornton, Vice President - Market Access
  • Yamo Deniz M.D., Chief Medical Officer
  • Mark P. Stejbach, Director

How do I buy Flexion Therapeutics stock?

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of Flexion Therapeutics stock can currently be purchased for approximately $24.28.


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Flexion Therapeutics (NASDAQ:FLXN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $88.50 (264.51% upside)
Consensus Price Target History for Flexion Therapeutics (NASDAQ:FLXN)
Price Target History for Flexion Therapeutics (NASDAQ:FLXN)
Analysts' Ratings History for Flexion Therapeutics (NASDAQ:FLXN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017LaidlawReiterated RatingBuy$35.00 -> $38.00N/AView Rating Details
10/10/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$570.00N/AView Rating Details
10/9/2017BMO Capital MarketsReiterated RatingOutperform$35.00 -> $37.00N/AView Rating Details
10/9/2017Needham & Company LLCBoost Price TargetBuy -> Buy$36.00 -> $42.00N/AView Rating Details
10/6/2017Wells Fargo & CompanySet Price TargetBuy$32.00 -> $39.00N/AView Rating Details
10/4/2017Northland SecuritiesReiterated RatingBuy$40.00MediumView Rating Details
9/11/2017Royal Bank Of CanadaSet Price TargetBuy$44.00LowView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
12/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Flexion Therapeutics (NASDAQ:FLXN)
Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Earnings History by Quarter for Flexion Therapeutics (NASDAQ FLXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.80)($0.91)ViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.79)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flexion Therapeutics (NASDAQ:FLXN)
Current Year EPS Consensus Estimate: $-3.85 EPS
Next Year EPS Consensus Estimate: $-3.32 EPS

Dividends

Dividend History for Flexion Therapeutics (NASDAQ:FLXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Flexion Therapeutics (NASDAQ:FLXN)
Insider Ownership Percentage: 15.98%
Institutional Ownership Percentage: 83.26%
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Yamo DenizInsiderBuy1,000$24.20$24,200.00View SEC Filing  
9/1/2017Yamo DenizInsiderBuy3,000$24.15$72,450.00View SEC Filing  
8/31/2017Yamo DenizInsiderBuy1,375$25.40$34,925.00View SEC Filing  
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.00View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.00View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.00View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.00View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.00View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.00View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.00View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.00View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.47View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.70View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.40View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.00View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.84View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.52View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.00View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.00View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.00View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.00View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.00View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.00View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.00View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.00View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.00View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.00View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.00View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.00View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.00View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Flexion Therapeutics (NASDAQ:FLXN)
Latest Headlines for Flexion Therapeutics (NASDAQ:FLXN)
Source:
DateHeadline
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - October 17 at 10:58 PM
finance.yahoo.com logoApplied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers
finance.yahoo.com - October 17 at 7:25 PM
benzinga.com logoJim Cramer Advises His Viewers On Flexion Therapeutics, Blackhawk Network And Carrizo Oil & Gas - Benzinga
www.benzinga.com - October 13 at 9:22 PM
nasdaq.com logoARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus - Nasdaq
www.nasdaq.com - October 12 at 1:19 AM
thestreet.com logoFlexion's Latest FDA Approval Reignites Takeover Chatter - TheStreet.com
www.thestreet.com - October 12 at 1:19 AM
globenewswire.com logoFlexion Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - October 12 at 1:19 AM
finance.yahoo.com logoFlexion Shares Lower After Proposed Stock Offering -- Biotech Movers
finance.yahoo.com - October 11 at 8:16 PM
finance.yahoo.com logoFlexion Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 11 at 8:16 PM
rttnews.com logoFlexion Therapeutics Inc. (FLXN) Is Falling On Offering News
www.rttnews.com - October 10 at 9:28 PM
finance.yahoo.com logoFlexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating
finance.yahoo.com - October 10 at 9:28 PM
finance.yahoo.com logoFlexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
finance.yahoo.com - October 10 at 9:28 PM
finance.yahoo.com logoFlexion CEO on non-opioid knee pain treatment
finance.yahoo.com - October 10 at 9:28 PM
finance.yahoo.com logoFlexion's Latest FDA Approval Reignites Takeover Chatter
finance.yahoo.com - October 10 at 4:27 PM
finance.yahoo.com logoFlexion Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 10 at 4:27 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Given "Buy" Rating at Laidlaw
www.americanbankingnews.com - October 10 at 3:50 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) PT Raised to $570.00
www.americanbankingnews.com - October 10 at 9:14 AM
streetinsider.com logoFlexion Therapeutics (FLXN) PT Raised to $42 at Needham & Company on 'FDA Approval for Zilretta with ... - StreetInsider.com
www.streetinsider.com - October 9 at 6:57 PM
benzinga.com logoFlexion Therapeutics Just Hit A Major Milestone - Benzinga
www.benzinga.com - October 9 at 6:57 PM
americanbankingnews.com logoBMO Capital Markets Increases Flexion Therapeutics, Inc. (FLXN) Price Target to $37.00
www.americanbankingnews.com - October 9 at 4:32 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Price Target Raised to $42.00
www.americanbankingnews.com - October 9 at 8:54 AM
nasdaq.com logoFDA OKs Flexion's Zilretta For Osteoarthritis Knee Pain
www.nasdaq.com - October 8 at 5:30 PM
streetinsider.com logoFlexion Therapeutics (FLXN) Receives FDA Approval of Zilretta for Osteoarthritis (OA) Knee Pain
www.streetinsider.com - October 7 at 9:14 PM
nasdaq.com logoFlexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release
www.nasdaq.com - October 7 at 12:08 AM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Given a $39.00 Price Target at Wells Fargo & Company
www.americanbankingnews.com - October 6 at 7:18 PM
marketwatch.com logoFlexion shares surge 18% on news of FDA approval for non-opioid knee pain injection - MarketWatch
www.marketwatch.com - October 6 at 7:08 PM
seekingalpha.com logoFDA OKs Flexion's Zilretta for osteoarthritis knee pain - Seeking Alpha
seekingalpha.com - October 6 at 7:08 PM
finance.yahoo.com logoFlexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoFlexion's knee pain drug gets FDA nod
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoFlexion shares surge 18% on news of FDA approval for non-opioid knee pain injection
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoBurlington biotech Flexion eyes expansion after FDA approves pain drug
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoFlexion shares surge on FDA approval for its non-opioid knee pain medication
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoFlexion soars on FDA drug approval
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoFlexion Secures FDA Nod for Osteoarthritis Knee Pain Treatment, Shares Skyrocket
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoEdited Transcript of FLXN earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoThis Biotech Could Reap North Of $1 Billion For Painkiller
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoFlexion's knee pain drug gets FDA nod, shares hit life high
finance.yahoo.com - October 6 at 7:07 PM
finance.yahoo.com logoStocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating
finance.yahoo.com - October 5 at 10:55 PM
fool.com logoBig Day on Deck for Flexion Therapeutics - Motley Fool
www.fool.com - October 5 at 5:55 PM
finance.yahoo.com logoWhat You Must Know About Flexion Therapeutics Inc’s (FLXN) Risks
finance.yahoo.com - October 5 at 8:55 AM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 4 at 6:02 PM
finance.yahoo.com logoOutlook for FDA Approval of Zilretta
finance.yahoo.com - October 4 at 5:39 PM
thestreet.com logoNotable Monday Option Activity: FLXN, VSM, PKE
www.thestreet.com - October 2 at 2:29 PM
finance.yahoo.com logo3 Biotech and Pharma Stocks with Key FDA Catalysts this October
finance.yahoo.com - October 2 at 2:29 PM
thestreet.com logoInteresting FLXN Put And Call Options For May 2018
www.thestreet.com - September 28 at 6:08 PM
americanbankingnews.com logoContrasting AveXis (AVXS) & Flexion Therapeutics (FLXN)
www.americanbankingnews.com - September 24 at 6:18 PM
nasdaq.com logoImplied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options - Nasdaq
www.nasdaq.com - September 19 at 11:46 PM
finance.yahoo.com logoImplied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options
finance.yahoo.com - September 19 at 6:43 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Given "Buy" Rating at Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
americanbankingnews.com logoInsider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,375 Shares of Stock
www.americanbankingnews.com - September 15 at 8:30 PM
americanbankingnews.com logoInsider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,000 Shares of Stock
www.americanbankingnews.com - September 15 at 8:30 PM

Social

Chart

Flexion Therapeutics (FLXN) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.